Cover Image
市場調查報告書

全球醫藥品·生物科技產業的潛力企業:隨著新標的等的發現,為疾病治療的創新療法注入新活力

Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.

出版商 MP Advisors 商品編碼 295954
出版日期 內容資訊 英文 72 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球醫藥品·生物科技產業的潛力企業:隨著新標的等的發現,為疾病治療的創新療法注入新活力 Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.
出版日期: 2015年01月21日 內容資訊: 英文 72 Pages
簡介

每當發現新標的和方法,生物醫藥品,便為全球各國的製藥企業以此為基礎之新疾病治療法的開發注入新活力。特別熱門的是幹細胞治療及再生醫療。但過多的企業加入讓互補有些困難,再加上再生醫療領域也又深又廣,本報告以近年來擁有應注意成果之企業為焦點,考察其成果及未來性。

本報告網羅有助於全球醫藥品·生物科技領域的藥物療法之創新與改善或可望有潛力之小規模研究專業企業,調查各企業的主要促進要素,競爭情形,其他開發平台藥物,市場機會及主要里程碑等。

第一部分:以再生醫療·幹細胞為基礎的細胞療法之潛力企業和未來的醫藥品

  • CESCA Therapeutics Inc.:解決以幹細胞為基礎的設備·治療方法的風險,打入海外
  • Ocata Therapeutics Inc:致力於眼病-黃斑再生的條件-注目於「新的眼睛」
  • Orgenesis:致力於糖尿病-讓肝臟能再次生產胰島素!
  • Tigenix NV:脂肪組織的活用-是否將打開脂肪的用途
  • Pluristem Therapeutics Inc:再生醫療與再利用-利用胎盤的自我移植治療
  • Mesoblast:韓國的再生醫療領導者-著重於國際市場
  • Medipost Co Ltd:韓國的再生醫療領導者-著重於國際市場
  • JCR製藥:日本第一個移植物抗宿主病(GVHD)用幹細胞型產品
  • Japan Tissue Engineering co:對再生醫療的自信-從Fujifilm轉換到再生醫療

第二部分:印度的創新企業 - 有未來潛力的企業

  • Connexios:為了提高能見度,致力於開發中產品的成熟化和對糖尿病/代謝症候群
  • Cellworks:In silico技術平台的普及預測 -著重於個人化醫療·癌症
  • Bugworks:提供嚴重的院內感染之In silico技術平台-現在馬上需要的技術
  • Tergene:低價格的第二世代疫苗 -配合新興國家市場的緊急需求

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 4477

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets , approaches and biology is discovered. One field which is poised to bring a paradigm change in the way diseases are treated in the next decades is the Stem cell therapy/Regenerative Medicine space.

The number of companies and products in the clinic have reached a critical mass warranting a close watch for those interested in keeping pace with the development of new medicines. The Regenerative medicine Universe is large and new companies are being added to it rapidly. As a result we have used some filters to select a few names for a detailed coverage in our Outlook this year.

Key Criteria for Our Selection are:-

  • Uniqueness of the Technology platform and the ability to scale up commercially in case of positive outcome of products in the pipeline
  • Pipeline and clinical data analysis
  • Marketed product and commercial tie up. Robustness of the Management, financial and business model.

Part 1- Rising Stars in Regenerative Medicine and Stem cell based Cell Therapies-Drugs of the Future

Company Analysis:

CESCA Therapeutics Inc.: Hedging the Risk with Stem Cell Based Devices and Therapies and Global Presence

  • Figure 1: Products In Pipeline
  • Table 1: Clinical Development- Critical Limb Ischemia (ClI)Data Key Milestones

Ocata Therapeutics Inc: Ophthalmic Focus- Macular degenerative conditions- Looking with a New Eye

  • Figure 1: Market For Age-Related Macular Degeneration (AMD)
  • Figure 2: Products In The Pipeline

Orgenesis: Focus- Diabetes- Tricking your Liver to Make Insulin!

  • Technology Platform
  • Figure 1: Schematic Representation Of Making Autologous Insulin Producing (AIP) Cell

Tigenix NV: Exploiting the Adipose Tissue- Multiple Applications of Fat?

  • Technology Platform
  • Marketed Products
  • Figure 1: Products In Pipeline
  • Key Milestones

Pluristem Therapeutics Inc: Regenerating and Recycling- Allogenic Therapies from the Placenta

  • PluriX 3D Technology Platform
  • Pipeline
  • Figure 1: Classification Of Peripheral Arterial Disease Types
  • Market Opportunity
  • Key Milestones

Mesoblast: Leader in Regenerative Sapce in Korea- Focusing on International Markets

  • Technology Platform
  • Pipeline- Focus on four major areas
  • Figure 1: Drugs In The Pipeline
  • Figure 2: CHFf Discease Classification And Target Patients In PhIII Trial
  • Figure 3: PhiII Data Of MPC-150 In CHF
  • Figure 4: Market Opportunity In Chronic Low Back Pain (CLBP)
  • Key Milestones

Medipost Co Ltd: Leader in Regenerative Space in Korea- Focusing on International Markets

  • Marketed and Products in the Pipeline
  • Key Milestones
  • Figure 1: Sales By Business Segment

JCR Pharmaceuticals co. Ltd.: First Stem Cell Based Product in Japan for Graft-Versus-Host Disease (GVHD).

  • Technology Platform
  • Product in the Pipeline
  • Key Milestones
  • Facts and Financials
  • Table 1: Pipeline Table
  • Figure 1: Sales By Business Segments

Japan Tissue Engineering co. Ltd: Building Confidence in Regenerative Medicine- Fuji film Venture from Colors to Regenerative Medicine-

  • Plat form Focus
  • Products
  • Figure 1: Therapy and Product Focus

Part II-Indian Innovators- Rising Stars:

Table 1: Select new generation innovation /drug discovery Indian companies

Connexios: Maturing Pipeline and Focus on Diabetes/Metabolic Disorders to Drive Visibility

  • Technology Platform
  • Therapy Focus-Diabetes/Metabolic Disorder and Non Alcoholic Steatohepatitis (NASH)
  • Key Milestones
  • Table 1: Differences Between G-Protein Coupled Receptor Agonists
  • Table 2: Pipeline Of GPR Agonist For Treatment Of Type 2 Diabetes
  • Figure 1: Products In Pipeline- Diabetes
  • Figure 2: Products In Pipeline For NASH
  • Figure 3: Other Programs

Cellworks: In silico Technology Platform Poised to Deliver- Focus on Personalised Medicine and Cancer

  • Figure 1: Simulation Based Personalized Medicine
  • Figure 2: Cellworks Therapeutic Programs

Bugworks: In silico Technology platform being applied to Serious Hospital Infections- Need of the hour!

  • Therapy focus- Serious Hospital Infection
  • Technology Platform
  • Figure 1: Drug Development Success For TB
  • Figure 2: Going Way Froward

Tergene: Affordable and Second Generation Vaccines- Addressing the Urgent needs of Emerging Markets.

  • Development Strategy and Status
  • Figure 1: Sales Of Currently Available Vaccines For Streptococcus Pneumonia
  • Figure 2: WW Demand Forecast Of Vaccines For Streptococcus Pneumonia
  • Figure 3: Vaccine Market
Back to Top